GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (STU:2XA) » Definitions » Other Gross PPE

Benevolent AI (STU:2XA) Other Gross PPE : €5.09 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Benevolent AI Other Gross PPE?

Benevolent AI's Other Gross PPE for the quarter that ended in Dec. 2023 was €5.09 Mil.

Benevolent AI's quarterly Other Gross PPE increased from Dec. 2022 (€4.32 Mil) to Jun. 2023 (€8.89 Mil) but then declined from Jun. 2023 (€8.89 Mil) to Dec. 2023 (€5.09 Mil).

Benevolent AI's annual Other Gross PPE increased from Dec. 2021 (€3.67 Mil) to Dec. 2022 (€4.32 Mil) and increased from Dec. 2022 (€4.32 Mil) to Dec. 2023 (€5.09 Mil).


Benevolent AI Other Gross PPE Historical Data

The historical data trend for Benevolent AI's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Other Gross PPE Chart

Benevolent AI Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial 2.20 2.71 3.67 4.32 5.09

Benevolent AI Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only 3.67 11.07 4.32 8.89 5.09

Benevolent AI Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Benevolent AI Business Description

Traded in Other Exchanges
Address
4-8 Maple Street, London, GBR, W1T 5HD
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.

Benevolent AI Headlines

No Headlines